These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35646158)

  • 1. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.
    Ben-Shatach Z; Ziv-Baran T; Fudim E; Yavzori M; Picard O; Levartovsky A; Selinger L; Weiss B; Kopylov U; Eliakim R; Ungar B
    Therap Adv Gastroenterol; 2022; 15():17562848221083395. PubMed ID: 35646158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
    Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Legaki E; Gazouli M; Koutroubakis IE
    Intest Res; 2021 Oct; 19(4):461-467. PubMed ID: 32806874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
    Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
    Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
    Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
    Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in young paediatric IBD patients: it is all about the dosing.
    Jongsma MME; Winter DA; Huynh HQ; Norsa L; Hussey S; Kolho KL; Bronsky J; Assa A; Cohen S; Lev-Tzion R; Van Biervliet S; Rizopoulos D; de Meij TGJ; Shouval DS; Wine E; Wolters VM; Martinez-Vinson C; de Ridder L;
    Eur J Pediatr; 2020 Dec; 179(12):1935-1944. PubMed ID: 32813123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab therapy intensification upon loss of response: Is there an optimal trough level?
    Ungar B; Ben-Shatach Z; Ben-Haim G; Yavzori M; Picard O; Fudim E; Kopylov U; Veyrard P; Del Tedesco É; Paul S; Eliakim R; Ben-Horin S; Roblin X
    Dig Liver Dis; 2019 Aug; 51(8):1106-1111. PubMed ID: 30928420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Choe YH
    Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
    Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
    Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
    J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Lee JH; Choe YH
    Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
    Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
    Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients.
    Reinhold I; Blümel S; Schreiner J; Boyman O; Bögeholz J; Cheetham M; Rogler G; Biedermann L; Scharl M
    Inflamm Intest Dis; 2021 Feb; 6(1):38-47. PubMed ID: 33850838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.